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1INTRODUCTION
Ischemic heart failure (HF) is a common complex
clinical syndrome following myocardial infarction and
is characterized by cardiac and non-cardiac features [1].
It is also the cause of mortality in high-risk patients
undergoing non cardiac surgery [2]. Despite the wide
use of different drugs, such as beta-blockers, an-
giotensin-converting enzyme inhibitors, angiotensin
receptor blockers, diuretics, or of devices, such as im-
plantable cardioverter-defibrillator and left ventricular
assist devices [3], the 5-year survival is worse than can-
cer. The past few decades have witnessed incessant re-
search aimed at protecting the adult myocardium
against ischemic injury, but the development of effec-
tive strategies to prevent the maladaptive tissue remod-
elling is still a desirable achievement [4]. Therefore, it
is clinically relevant to address further studies to dis-
sect alternative pathophysiological issues, such as cell-
to-cell and cell-to-microenvironment cross-talk during
the exposure to ischemic insult. Epigenetic modifica-
tions mediate mechanisms underline cellular tolerance
against ischemic microenvironment, as cell survival
and angiogenesis [5]. Despite the threshold of adaptive
epigenetic effects is difficult to be safely modulated by
synergistic drug combinations, the intramyocardial de-
livery of low doses of specific natural compounds has
protected the ischemic myocardium through the mod-
ification of the epigenetic profile of cardiomyocytes,
endothelial and interstitial cells [6]. Our first experi-
mental evidence demonstrates the feasibility of cardio-
protection by biocative compounds also present at
higher concentrations in conventional plant foods
named functional foods. To date, the regular intake of
functional foods may be helpful to reduce cardiovascu-
lar risk factors [7] and to prevent the onset of the re-
modelling process of ischemic myocardium. 
OVERVIEW OF MYOCARDIAL TARGETS
OF CARDIOPROTECTION 
The cardiac remodeling recapitulates cellular, intersti-
tial, molecular and genetic changes after an initial injury.
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Abstract. Epigenetic changes affect the gene expression profile of cells without altering the DNA sequence in response to
different environmental stimuli, such as the diet. Several dietary plant compounds have the epigenetic ability to prevent both
the onset and the progression of different diseases, including cardiovascular diseases that are one of the most common in the
world. Heart failure following perioperative myocardial infarction is a complex clinical syndrome without cure, also affecting
high-risk patients undergoing non-cardiac surgery. It is characterized by serious decay of cardiac pump function as a result
of ongoing remodelling of the myocardium. Despite the increasing use of conventional medications has reduced the mortality
of patients with myocardial infarction, the outcome remains unpredictable so far. The past three decades have witnessed in-
cessant research aimed at protecting the adult myocardium against ischemic injury, but the development of effective strategies
to prevent the maladaptive tissue remodelling is still a desirable achievement. Recent findings reveal that the dietary intake
of natural bioactive components with known antioxidant activity improves the intercellular communication and increases
the tolerance of both cardiomyocytes and coronary endothelial cells against the ischemic microenvironment. The Epigenetic
activation of rescue genes prevents the decay of function of the abovementioned cardiac cells. Consequently, this scenario
would reduce the myocardial accumulation of collagen responsible for the tightening of the heart walls. Whereas the non-
invasive delivery of cardioprotectant epigenetic compounds through diet is a promising approach, regulatory mechanisms
need to be unravelled. 
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The cardiac remodelling process itself is compensatory
at early stage and detrimental in the long term [8]. The
early inflammatory cell-mediated response is helpful to
remove cell debris and to counteract the release of pro-
apoptotic mediators, which leads to the activation of en-
dothelial cells and fibroblasts to form new vessels and
to promote adaptive hypertrophy respectively. After-
wards, collagen-rich scar replaces the loss of mature my-
ocardium. The chaotic and rapid stimulation of
intracellular pathways triggers cardiomyocytes and pro-
genitor cells death, rarefies the native net of the coronary
microcirculation, which is replaced by immature ves-
sels, and deregulates the extracellular matrix turnover
as well. This rescue scenario becomes over time a vi-
cious circle leading to irreversible myocardial damage.
Specific targets for the prevention of cardiac failure will
be revised within interplay between dynamic and
pleiotropic signaling pathways. 
THE SURVIVAL OF CARDIOMYOCYTES
AND PROGENITOR CELLS
Cardiac progenitor cells and cardiomyocytes survive
in the presence of hostile microenvironment by multi-
ple mechanisms and the magnitude of cell survival
varies regardless the etiology and exposition time. The
regulation of survival of cardiac cells is very important
both to maintain the homeostasis of normal adult my-
ocardium [9] and to limit the remodeling process dur-
ing the exposure to insults [10-14]. To date, the
prosurvival pathways counteract different form of cell
death, such as apoptosis, oncosis and autophagy, in
normal and injured adult myocardium [15]. 
Apoptosis is an active and highly regulated biologi-
cal process. Two main apoptotic pathways transduce
death signals in cardiac cells: i) the intrinsic pathway
occurs through the opening of the mitochondrial per-
meability transition pore or the rupture of outer mito-
chondrial membrane. The cleavage of
caspase-9/caspase-3 cascade is mediated by cy-
tochrome c, which is released by mitochondria after ex-
posure to hypoxia, ischemia–reperfusion injury, and
oxidative burst. Finally, the active caspase-3 cleaves
cardiac cytoskeletal proteins, such as α-actin, α-actinin,
α/β-myosin heavy chain, myosin light chain 1/2,
tropomyosin and troponins [16]; ii) the extrinsic path-
way involves the stimulation of pathways mediated by
death-receptors, such as the Fas receptor or the tumor
necrosis factor α receptor-associated death domain pro-
tein (TRADD) [17]. Even if the death-receptors do not
necessarily cause cell death, the binding of each death-
receptor to its ligand induces the formation of a death-
inducing signaling complex (i.e.: TL1A/DR3;
TRAIL/TRAILR) which activates caspase-8 [18]. The
magnitude of apoptosis into the heart is regulated
through the expression of: a) anti-apoptotic factors,
such as Bcl-2, XIAP (X chromosome-linked Inhibitors
of Apoptotic Proteins), ARC (apoptosis regulator with
caspase recruitment domain), c-FLIP(L) (an endoge-
nous inhibitor of death receptor-induced apoptosis
through the caspase-8 pathway), Foxo3a (a regulator
of calcium level) and microRNA (miRNA)-702 (a
downregulator of activating transcription factor 6); b)
pro-apoptotic factors, such as Bax and Bak, Smac/DI-
ABLO, XIAP-interacting protein-1 and Omi/HtrA2
(IAPs inhibitors) [19].
Oncosis, conversely, is a non apoptotic cell death char-
acterized by rapid depletion of intracellular ATP [19],
mitochondria swelling due to the failure of the surface
ionic pumps and progressive plasma membrane disrup-
tion, followed by an inflammatory reaction [19]. Onco-
sis is a major contributor to myocardial ischemic cell
death [20] and may be independent of caspases activa-
tion [20]. 
Although, autophagy is a process characterized by
lysosome-dependent degradation and recycling of intra-
cellular elements, such as dysfunctional mitochondria
[21]. It characterizes a conservative response to different
insults. Macroautophagy is the main form of autophagy,
where plasma membrane enveloping a large portion of
the cytosol forming the autophagosomes. The au-
tophagosomes fuse with lysosomes to form autolyso-
somes [22]. Further studies also detected the occurrence
of microautophagy, which is the transfer of small cytoso-
lic components into the lysosome by membrane vesicles
[23], and chaperone-mediated autophagy, which is the
direct shuttling of soluble cytosolic proteins into lyso-
somes by chaperone (i.e.: heat shock protein of 70 kDa)
[24]. 
Deregulated autophagy leads to cell death and car-
diac dysfunction through uncontrolled self-digestion
of cellular constituents [25]. Even if much remains to
be elucidated, AMP-activated protein kinase (AMPK),
an important regulator of cardiac metabolism [26],
serves as an activator of myocardial autophagy through
activation of E3 ligases expression [27]. miRNA-325
contributes also to promote autophagic cell death [25]. 
THE TURNOVER OF CORONARY VESSELS
The capillary density and the capillary-to-myocyte
ratio influences the effectiveness of the myocardial
blood perfusion in response to increasing load, which
is critical to support cardiac contractile function [28].
The rarefaction as well as the dysfunction of the micro-
circulatory net following myocardial ischemia impairs
the restoration of the blood supply in infarcted my-
ocardium [29]. The capillary density is maintained by
a balanced turnover of endothelial cells proliferation
and migration, sprouting and tube formation. New
coronary microvessels are generated from pre-existing
mature endothelial cells in response to different sig-
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3nals, such as hypoxia [30], oxygen free radicals (ROS)
[31], growth factors (VEGF, HGF, FGF, Notch-1 and
PDGF-β) [16,32], C-type natriuretic peptide [33] or ni-
tric oxide (NO) [34]. Conversely, the coronary angio-
genesis is hampered by chronic inhibition of
endothelial NO synthase [35] and by different soluble
factors. The main endogenous inhibitors of angiogen-
esis are angiostatin, endostatin [36] and miRNA-24
[37].
Interestingly, the endothelial ability to renew the
capillary network architecture is controlled via cell-ma-
trix mechanical interactions [38] and shear stress [39].
THE TURNOVER OF EXTRACELLULAR
MATRIX 
The turnover of cardiac extracellular matrix (ECM)
provides a balance of elastic and plastic structures sup-
porting cardiomyocytes, interstitial cells and capillaries
in order to optimize the mechanotransduction, the elec-
trical conductivity and permittivity, the intercellular
cross-talk, and metabolic activity in the presence of dif-
ferent microenvironment [40]. This issue is critical be-
cause the features of ECM change during early and late
remodeling process. In particular, glycosaminoglycans
(i.e: heparan sulfate, hyaluronan), glycoproteins (i.e:
tenascin-C) and proteoglycans (i.e.: lumican) play a key
role in ECM formation [40]. Extracellular Granzyme B
and metalloproteinases (MMPs), bioactive serine pro-
teases, contribute to the loss of myocardial structural
integrity through cleavage of ECM proteins [41,42].
Other factors may interfere with the renew of ECM in
normal heart and with fibrosis during remodelling. In
particular, the connective tissue growth factor (CTGF),
a secreted cysteine-rich protein, highly expressed in
both cardiac fibroblasts and cardiomyocytes of failing
heart [43], enhances the expression of fibronectin and
collagen type 1 through the activation of TGF-beta-de-
pendent pathways. Finally, CTGF expression is epige-
netically down regulated by selective microRNAs, such
as miRNA-133 and miRNA-30 [44]. 
THE INNATE IMMUNITY APPARATUS: 
CROSS-TALK BETWEEN MYOCARDIAL
SENSORS
Innate immune apparatus triggers inflammatory re-
sponse. In particular, toll-like receptor-mediated path-
ways and cardiac progenitor cells modulate the release
of soluble auto-/paracrine factors, such as chemokines,
cytokines and exosomes in the injured heart [45]. 
Cardiac progenitor cells, endothelial cells, fibroblasts
and mast cells, which are resident in the adult heart
[46], express auto-/paracrine mediators able to activate
or to silence gene profile and function in response to
changes of microenvironment and tissue geometry
[32].
Toll-like receptors (TLRs), such as TLR-2, TLR-3 and
TLR-4, are recognition receptors expressed by all cells
resident into the adult heart and mediates immune-me-
diated pathways activity during myocardial remodelling
[47]. Endogenous products of myocardial remodelling,
such as free radicals, heat shock proteins and hyaluro-
nan, activate several kinases and NF-kB through TLRs,
which promote the expression of inflammatory media-
tors [47] acting as endogenous preconditioning agents
[48]. 
Even though clinical trials have reported unconvinc-
ing results on the renew of cardiomyocytes in infarcted
myocardium by progenitor/stem cells [49], cardiac pro-
genitor cells are able to polarize human macrophages
into an anti-inflammatory phenotype promoting the re-
lease of angiogenic and anti-inflamamtory cytokines,
such as VEGF, IL-10 and IL-13, to inhibit the release
of pro-inflammatory cytokines, such as IL-1α, IL-17
and interferon gamma [50] and to induce the release of
membrane-surrounded nanovesicles, termed exo-
somes, activating pro-survival signaling pathways in
cardiomyocytes involving TLR 4 and HSP27 (48). This
mechanism highlights the role of myocardial progeni-
tor cells as critical regulator of cell-to-cell communica-
tion in the adaptive response of cardiac cells to
ischemic microenvironment [51]. 
EPIGENETIC MODULATION
OF CARDIOPROTECTION 
The epigenetic code refers to specific heritable chro-
matin-based regulatory mechanisms underlie the regu-
lation of gene expression without altering DNA
sequence [52]. Epigenetic pathways mediate the tran-
scriptional and post-transcriptional modifications of
gene profile also in cardiac cells. Three main pathways
regulate the epigenetic state of the heart: DNA methyla-
tion, histone modifications, and RNA-based silencing.
DNA methylation refers mainly to the addition of a
methyl group to the 5-position of cytosine of CpG se-
quence of promoter regulatory regions through selec-
tive enzymes [5]. The cells use DNA methylation to
lock gene trascription in the off position by three mech-
anisms: i) the blocking of recruitment of transcription
factors to correspondent cis-DNA binding elements by
steric hindrance, ii) the specific co-binding of proteins
to methylated DNA that compete with the specific tran-
scriptional factors [53] and iii) the recruitment of his-
tone deacetylases (HDACs) to silence gene expression
[54]. The gene donwregulation through the global
gene promoter methylation is a typical feature of the
end-stage failing myocardium in humans [55]. 
Histone modifications alter the gene expression
through changes in the nucleosome conformation in
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order to control DNA accessibility. The nucleosome rep-
resents the chromatin unit and is composed of 146-bp
DNA wrapped around octamers formed of four couple
of different highly alkaline nuclear proteins termed hi-
stones (H2A, H2B, H3, and H4). Histones undergo to
different posttranslational modifications at level of ly-
sine (acetylation, ubiquitination, methylation, sumoly-
ation) or arginine (methylation) or serine and threonine
(phosphorylation) residues [5]. Reversible histone
acetylation plays a key role in the development of post-
ischemic myocardial remodelling. The magnitude of
myocardial histone acetylation, which usually activates
gene transcription, is regulated by the balance of the ac-
tivity of two different enzymes: a) histone acetlytrans-
ferase (HAT), such as p300/CREB-binding protein,
which transfers acetyl group to histones and prevent
chromatin compaction, and b) histone deacetylase
(HDAC), which removes acetyl group from conserved
lysine residues of H3 and H4 histone and leads to the
formation of unreadable chromatin. There are four major
classes of HDACs, which randomly act to control gene
expression in cardiac cells exposed to hostile microen-
vironment. We and other investigators have demon-
strated that the inhibition of the class I HDACs in
cardiac cells is able to inhibit apoptosis and to stimulate
angiogenesis through acetylation of H4 histone. Taken
together, these biological events limit structural remod-
elling and improve the cardiac function in vivo [6,56]. Fi-
nally, phosphorylation of histone H2A(X) is essential to
repair damaged DNA [57]; although, phosphorylation
of histone H3 promotes cell proliferation and promotes
gene transcription through acetylation of H3K14 by the
Gcn5 acetyltransferase [58]. 
MicroRNA (miRNAs) and the RNA interference ma-
chinery are endogenous key repressors of chromatin-
based gene expression [5]. Most miRNAs genes are
located at level of the intergenic, intronic, or exonic re-
gions of DNA and are transported from the nucleus to
the cytoplasm as part of mRNA. The mature miRNAs are
incorporated into a miRNA-induced silencing complex
(RISC) and base-paired to target mRNA for mRNA
degradation [59]. Cells secrete miRNAs, small non-cod-
ing RNA molecules, into exosomes [60]. To date, it is
known that miRNAs profile is altered in failing my-
ocardium [61], which plays a key role in the impairment
of the cardiac structure-function relationship. In fact, the
upregulation of miRNA25 in failing heart delays myo-
cytes calcium uptake and causes decay of contractility in
vivo [62]. Similarly, the over-expression of miRNA 30c
and miRNA 155 promote cell loss through alteration of
the mitochondrial function [63]. miRNA 21 mediates fi-
broblast survival and proliferation [64]; although,
miRNA21* delivered to cardiomyocytes through fibrob-
last-derived exosomes induce hypertrophy in response
to hostile microenvironment [65]. Other miRNAs might
play an activator role in promoting myocyte prolifera-
tion in murine infarcted heart. For example, the myocar-
dial overexpression of miRNA 590 and miRNA 199a
promote cardiomyocyte proliferation and almost com-
plete recovery of cardiac functional parameters in
murine infarcted heart [66]. We have demonstrated that
exosomal miRNA 210 prevents cardiomyocytes apopto-
sis in infarcted heart through downregulation of its
known targets, ephrin A3 and protein-tyrosine phos-
phatase 1B (PTP1b); although, exosomal miRNA 132
enhances the formation of mature coronary vessels
through downregulation of RasGAP-p120 [60]. 
PRIMARY PREVENTION
WITH FUNCTIONAL FOODS
Primary prevention of cardiac dysfunction is based
on the avoidance or attenuation of risk factors in
healthy people.
The main risk factors promoting myocardial injury are
age, gender, lifestyle factors (i.e.: lower physical activity,
occupational stress, smoking, excessive caloric an salt in-
take, excessive alcohol and coffee consumption, lower
socioeconomic status) and comorbidities (i.e.: hyperten-
sion, diabetes, obesity, hyperlipidemia, depression and
valvular heart disease) [67]. Even if some risk factors
cannot be avoided, such as age, gender and genetic sus-
ceptibility to cardiomyopathy, lifestyle risk factors and
comorbidities might be modulated by intake of func-
tional foods, such as plant or marine foods, which con-
tain higher amount of bioactive compounds
(nutraceuticals). 
Foods lowering hypertension
In young subject, the diastolic blood pressure is a risk
factor for HF more relevant than systolic blood pressure;
although, the impact of systolic blood pressure increases
in older patients [1]. Despite the conventional anti-hy-
pertensive medications are effective in normalizing
blood pressure with combination of two or more drugs,
natural dietary compounds are emerging as inhibitor of
vascular and myocardial remodelling following the ex-
posure to high blood pressure. Recent double-blind ran-
domised placebo-controlled trials have demonstrated
that the daily intake of non-fresh garlic extract (at aver-
age dose of 2.4mg/day for 12 weeks) causes a significant
reduction of the mean systolic blood pressure in patients
with refractory systolic hypertension [68]. The anti-hy-
pertensive effects of garlic is partly due to production of
NO [69]. However, so far, there is no clinically relevant
evidence to claim that regular garlic intake reduces the
risk of mortality and cardiovascular morbidity in hyper-
tensive patients [70]. 
Other pilot study has shown that oral pea protein hy-
drolysate has a weak and significant blood pressure-
lowering effect in hypertensive subjects through
inhibition of renin and angiotensin converting enzyme
[71]. Conversely, no blood pressure-lowering effect
was observed in hypertensive patients following di-
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5etary intake of theobromine-enriched flavanol-rich
chocolate [72], with known antioxidant properties.
Relevant clinical research activity has shown that the
most potent dietary antihypertensive compound is the
n-3 fatty acid α-linolenic acid (ALA) [73], which is con-
tained at higher concentration in flaxseed [74]. Ran-
domized, double-blinded, controlled trial confirmed
that intake of 30 g of milled flaxseed/day for 6 months
significantly reduces the systolic blood pressure and
the risk of ventricular remodelling in hypertensive pa-
tients [75]. In fact, high plasma ALA levels inhibit sol-
uble epoxide hydrolase and reduces circulating level
of oxylipins, which cause endothelial dysfunction and
atherosclerosis [76]. 
Foods lowering hyperlipidemia
Hyperlipidemia, in particular high levels of non-
high-density lipoprotein cholesterol, is a primary risk
factor for myocardial injury [77]. Since the progression
of myocardial injury towards heart failure depends on
the time exposure to hyperlipidemia, it is conceivable
to prevent myocardial injury through diet supplemen-
tation with specific functional foods lowering lipids in
the bloodstream. 
Recent randomized controlled clinical trials have
demonstrated that daily intake of functional foods con-
taining high levels of plant-derived protein hydrolysates
and peptides reduces the circulating cholesterol levels
in a dose-dependent manner [78]. In particular, regular
intake of plant stanols and sterols (2 g/day) [79], barley
β-glucans (3 g/day) [80] or tree nuts [81,82] reduces cir-
culating LDL-cholesterol (LDL-c) serum levels. In hy-
perlipidemic patients, 6-months intake of diet
containing both of the abovementioned compounds was
more effective in LDL-C lowering compared to the in-
take of low-saturated fat diet [83]. Therefore, the hypoc-
holesterolemic effects of these compounds are
independent of the caloric intake. Other dietary plant-
derived compounds normalize the lipid profile in dis-
lipidemic patients with normal cardiac function. For
example, pectin with high molecular weight and high
degree of esterification (contained in lemon and apple),
when taken at dose of 6 g/day for 3 weeks, are effective
in reducing LDL-c levels in mildly hypercholesterolemic
patients [84]. Similarly, red grape seed extract, when
consumed at dose of 200 mg/day for 8 weeks, decreases
both the oxidized-LDL levels and the risk of atheroscle-
rosis and cardiovascular disorders in mild hyperlipi-
demic subjects [85]. Grape seeds contain high levels of
flavonoids, such as gallic acid and procyanidins, with
epigenetic properties (HAT inhibitors) [86]. Conversely,
the cholesterol-lowering effects of phenolic-rich virgin
olive oil, which is an important component of the
Mediterranean diet, are still controversial and need fur-
ther investigations [87]. This finding is surprising if we
consider that a Mediterranean diet supplemented with
extra-virgin olive oil or nuts reduces the incidence of
major cardiovascular events in persons at high cardio-
vascular risk [88]. Similarly, some animal-derived func-
tional foods have shown significant effects in reducing
human cardiovascular risk due to exposure to hyperlipi-
demia. Recent randomized placebo-controlled study has
demonstrated that daily intake for 10 weeks of yoghurt
supplemented with 3 g of n-3 long-chain polyunsatu-
rated fatty acids (PUFA) significantly reduced the circu-
lating levels of inflammatory mediators and the
cardiovascular risk in mildly hypertriacylglycerolemic
patients [89]. The comparison between the cholesterol-
lowering efficacy of plant- and animal-derived foods re-
main to be fully assessed. So far, it is known that
long-term dietary intake of fish oil (17 g/day for 8
weeks), which is rich of n-3 PUFA, decreases only
triglyceride serum levels in patients with metabolic syn-
drome; although, the dietary intake of similar dose of
echium oil, a plant extract of Echium plantagineum rich
of stearidonic acid, causes a marked reduction of serum
triglyceride and oxidized LDL in the same class of pa-
tients [90].
Foods restoring insulin sensitivity
The insulin resistance (IR) strongly characterizes the
type 2 diabetes as well as the more complex metabolic
syndrome, which are independent risk factors for HF.
Recent findings confirmed that chronic insulin resist-
ance itself impairs cardiac homeostasis through the in-
duction of inflammatory and oxidative burst related to
the metabolic myocardial state following endothelial
dysfunction [91]. Conventional therapies for insulin
resistance partly fail to prevent and to reverse both
high fasting plasma glucose and myocardial injury.
Therefore, it is conceivable to develop innovative di-
etary-based strategies against IR based on the intake
of functional foods [92]. It has been demonstrated that
daily intake for one month of both whole and fraction-
ated pea flour (50 g/day) is effective in reducing IR in
overweight patients with metabolic syndrome [93].
Similarly, the daily supplementation of low cholesterol
diet with 40g of ground flaxseed-containing baked
products improves the insulin sensitivity in hyperlipi-
demic adults [94]. The IR-lowering effects were ob-
served in obese population with pre-diabetes and in
patients with metabolic syndrome long-term treated
with plant-derived n-3 ALA (flaxseed, rapeseed oil)
[95,96]. 
Even though the benefits require further investiga-
tions, the use of antioxidants seems to be a promising
approach to reduce the insulin resistance in an epige-
netic manner. In fact, long-term dietary intake of broc-
coli sprouts powder (10 g/day), which contains high
levels of sulphoraphane, a potent inhibitor of class I
HDACs, significantly reduces serum insulin levels and
homoeostasis model assessment of IR (HOMA-IR)
index in type 2 diabetic patients [97]. However, further
studies are mandatory to exclude the inhibition of glu-
cose-induced insulin secretion after the long-term in-
take of lower dose of sulphoraphane [98].
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SECONDARY PREVENTION
WITH FUNCTIONAL FOODS
Secondary prevention of cardiac dysfunction is fo-
cused on the prevention of late myocardial remodelling
in patients with current symptoms of ischemic heart
diseases (i.e.: angina, myocardial infarction, recipients
of coronary revascularisation, cardiac amyloidosis, ar-
rhythmias) or with symptoms of other vascular dis-
eases (such as stroke, peripheral vascular diseases).
The aim of secondary prevention is to prevent progres-
sion of the primary myocardial injury. The conven-
tional interventions of secondary prevention are based
on drugs (i.e.: low dose aspirin, statins, β-blockers, an-
giotensin converting enzyme (ACE) inhibitors, in-
hibitors of platelet aggregation) and changes of
lifestyle habits (i.e.: physical activity, diet, meticulous
control of blood pressure and glucose, cognitive activ-
ity). Emerging pre-clinical evidences have shown that
regular intake of selected functional foods might ham-
per the post-ischemic myocardial remodelling in dam-
aged hearts. Flavonoids, such as anthocyanins, are
common anti-oxidant compounds of plant-derived
functional foods and their regular intake after is-
chemia-reperfusion injury improves cardiac function
in rats [99]. Similar benefits are induced with short-
term oral administration of beta-glucan in a swine
model of myocardial ischemia/reperfusion [100] and
in a canine model of myocardial infarction [101]. In ad-
dition, short-term dietary intake of cooked broccolis
can limit the infarct size of murine hearts exposed to
ischemia-reperfusion injury [102]. While the mecha-
nisms are still under investigation, it is conceivable
that the cardioprotection is due to the inhibition of
class I HDACs by sulphoraphanes contained in broc-
colis [103]. We have demonstrated that long-term treat-
ment of cultured endothelial cells and Tg (kdrl: EGFP)
s843Tg zebrafish embryos with 3% barley beta-glucan
enhances the formation of new vessels in the presence
of ischemic microenvironment through the increased
acetylation of histone H4, which is related to higher
levels of manganese superoxide dismutase, a key an-
tioxidant enzyme, and NO [104]. Similarly, our recent
preliminary data have shown that the long-term intake
of low-fat diet supplemented with functional pasta de-
livering 3% barley beta-glucan increases the VEGF-
mediated myocardial capillary density and attenuates
the ischemia/reperfusion injury in murine heart
through the increase of native collateral formation after
5-weeks of diet [105]. In addition to these recent pre-
clinical evidences, placebo-controlled, double-blind
randomised clinical trial has demonstrated that the
supplementation of diet with vitamin D, able to induce
hitone acetylation and DNA demethylation [106], did
not improve the endothelial function in patients with
myocardial infarction [107]. It is conceivable that this
negative finding is related to the hormetic regulation
of the epigenetic state. In fact, the co-treatment of cells
with active vitamin D, HDACs inhibitors and DNA
methyltransferase inhibitors induces apoptosis of can-
cer cells [108], an effect induced by the exposure to
highest dose of chromatin openers. Similarly, the broad
use of antioxidants increases the risk of HF in patients
with acute myocardial ischemia [109]. These findings
suggest that the cardioprotective efficacy of functional
foods mainly depends on the epigenetic magnitude of
natural compounds in the presence of different mi-
croenvironment, but it does not depend on antioxidant
activity. Finally, the epigenetic role of dietary antioxi-
dant compounds in modulating the expression of my-
ocardial microRNAs is emerging. The synergistic
action of antioxidant resveratrol, a constituent of red
wine, and alpha-tocotrienol, a compound of palm oil,
is able to increase the myocardial expression of anti-
angiogenic miRNA20b, which is not reflected in the
cardioprotection against ischemia/reperfusion injury
[110]. In fact, other investigators have demonstrated
that the anti-angiogenic properties of the resveratrol
are counteracted by its ability to increase NO-depen-
dent vasodilation [111]. Otherwise, the intake of anti-
inflammatory curcuminoids (4 g/day from 3 days
before until 5 days after the surgery), polyphenols able
to demethylate the DNA [112], prevented the onset of
myocardial infarction in 121 patients undergoing coro-
nary artery bypass grafting [113]. Experimental and
clinical investigations are on-going in order to further
unravel epigenetic mechanisms underlie cell-to-cell
and cell-to-matrix interactions in injured hearts,
which are candidate targets of dietary bioactive com-
pounds.
CONCLUSIONS AND PERSPECTIVES
Dietary functional compounds have been gaining in-
terest, so far. Since the relationship between epigenetic
state and myocardial remodelling becomes more well-
defined, the identification of key molecular targets is
helping to reveal new natural epigenetic compounds
mainly contained in conventional plant-derived foods.
These findings will be useful to design hitherto unex-
pected dietary approach in order to prevent both the
myocardial injury and the development towards heart
failure. Moreover, some relevant issues on pleiotropic
epigenetic effects of natural compounds will also en-
courage further studies in order to reduce the dose of
conventional drugs and to improve the outcome of sub-
jects exposed to high cardiovascular risks.
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